---
title: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
date: '2024-04-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38587233/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240408180508&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with obesity-related heart failure with
  preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions
  in heart failure-related symptoms and physical limitations and greater weight loss
  than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, ...